title: Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
abstract: Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. We evaluated the prognostic significance of serum soluble CD27 (sCD27) in 143 patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone plus rituximab (R-CHOP). Five-year overall survival rates for patients with sCD27≥213 U/mL or <213 U/mL were 38.7% and 76.8%, respectively (p =0.0005). Multivariate analysis revealed that serum sCD27 was significantly correlated with OS (p =0.047). Immunohistochemical staining for CD27 in lymphoma tissues revealed positive lymphoma cells in 22 cases (18.5%) and positive microenvironment T-cells in 62 cases (52.1%) and was negative in the remaining patients. In these three subgroups, median sCD27 levels were 336 U/mL, 242.6 U/mL and 109.9 U/mL, respectively (p =0.004). Thus, serum sCD27 level is associated with CD27 expression on lymphoma cells, and may be a powerful prognostic factor for DLBCL.
authors.affiliation: First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Masao
authors.initials: M
authors.lastname: Takemura
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yasuda
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.forename: Michio
authors.initials: M
authors.lastname: Sawada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yamada
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Seishima
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008954:Models, Biological; D015999:Multivariate Analysis; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction; D015203:Reproducibility of Results; D000069283:Rituximab; D016896:Treatment Outcome; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000097:blood*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone